[
  {
    "patient_ID": "TCGA.A3.3317",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 605,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 886,
    "drug_units": "MG",
    "drug_dose": 800,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.A3.3317",
    "drug_therapy_name": "INTERFERON ALFA",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 605,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 886,
    "drug_units": "M[IU]",
    "drug_dose": 0.5,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.A3.3347",
    "drug_therapy_name": "PERIFOSINE",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1097,
    "pharmaceutical_tx_ongoing": false,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.A3.3347",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "pharmaceutical_tx_ongoing": false,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.AK.3426",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 465,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 522,
    "drug_dose": 3,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.AK.3436",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 76,
    "pharmaceutical_tx_ongoing": true,
    "drug_units": "MG",
    "drug_dose": 37.5,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.AK.3436",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 1194,
    "pharmaceutical_tx_ongoing": true,
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.AK.3453",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "regimen_number": 1,
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.B0.4718",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 99,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1231,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.4718",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 1363,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1685,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "patient_ID": "TCGA.B0.4837",
    "drug_therapy_name": "TYROSINE KINASE INHIBITOR",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 1217,
    "pharmaceutical_tx_ongoing": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.4841",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 108,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.4844",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.4844",
    "drug_therapy_name": "THALIDOMIDE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5094",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 124,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5107",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 11,
    "pharmaceutical_tx_ongoing": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5115",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 197,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 197,
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5115",
    "drug_therapy_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 501,
    "pharmaceutical_tx_ongoing": true,
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5694",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 441,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 469,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5701",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 366,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 727,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B0.5712",
    "drug_therapy_name": "ZOMETA",
    "days_to_drug_start": 177,
    "pharmaceutical_tx_ongoing": false,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.B2.5639",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 158,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_total_dose_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 275
  },
  {
    "patient_ID": "TCGA.B2.5639",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 177,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 241,
    "drug_units": "MG",
    "drug_dose": 200,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.B8.4143",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 388,
    "drug_cycles": 3,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTATIC DISEASE AT DIAGNOSIS"
  },
  {
    "patient_ID": "TCGA.B8.4153",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 238,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.B8.5162",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": -58,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": -28,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "patient_ID": "TCGA.BP.4161",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2752,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4165",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2594,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 19,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4169",
    "drug_therapy_name": "AXITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 127,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 253,
    "drug_cycles": 6,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4169",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 78,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4329",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 190,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 510,
    "drug_dose": 9000000,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4329",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 204,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 510,
    "drug_units": "MG",
    "drug_dose": 15,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4334",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 520,
    "pharmaceutical_tx_ongoing": false,
    "drug_dose": 6000000,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4335",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 134,
    "drug_cycles": 4,
    "drug_units": "MG/KG",
    "drug_dose": 4.5,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4338",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1765,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 2450,
    "drug_cycles": 17,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4338",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2460,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 2572,
    "drug_cycles": 4,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4338",
    "drug_therapy_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 2586,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_dose": 10,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4352",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 59,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PALLIATIVE"
  },
  {
    "patient_ID": "TCGA.BP.4354",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 454,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "patient_ID": "TCGA.BP.4354",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 595,
    "pharmaceutical_tx_ongoing": false,
    "drug_units": "MG",
    "drug_dose": 200,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.BP.4354",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 721,
    "pharmaceutical_tx_ongoing": true,
    "regimen_number": 5,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "PATIENT CANNOT TOLERATE SORAFENIB"
  },
  {
    "patient_ID": "TCGA.BP.4354",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 583,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 589,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4354",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 490,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 525,
    "drug_cycles": 3,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.BP.4354",
    "drug_therapy_name": "GEFITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 454,
    "drug_cycles": 11,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "patient_ID": "TCGA.BP.4770",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 211,
    "pharmaceutical_tx_ongoing": false,
    "drug_dose": 5000000,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4787",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 333,
    "drug_cycles": 7,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "patient_ID": "TCGA.BP.4787",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 361,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 388,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4787",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 412,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 440,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4804",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1373,
    "pharmaceutical_tx_ongoing": true,
    "drug_units": "MG",
    "drug_dose": 37.5,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "DOSE REDUCTION"
  },
  {
    "patient_ID": "TCGA.BP.4804",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1289,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1359,
    "drug_cycles": 2,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4974",
    "drug_therapy_name": "GEFITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 59,
    "drug_cycles": 1,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4974",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 58,
    "drug_cycles": 1,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.4974",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 155,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "RE-STARTED TREATMENT"
  },
  {
    "patient_ID": "TCGA.BP.4974",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 178,
    "pharmaceutical_tx_ongoing": false,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "patient_ID": "TCGA.BP.4985",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 307,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 728,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.5009",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 338,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 577,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "RECURRENT AND METASTATIC"
  },
  {
    "patient_ID": "TCGA.BP.5009",
    "drug_therapy_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 609,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1023,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_dose": 10,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.5009",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1029,
    "pharmaceutical_tx_ongoing": false,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "patient_ID": "TCGA.BP.5009",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 765,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 765,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 800,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.5178",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 407,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 772,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.5189",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 661,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 773,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.5189",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 794,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 794,
    "drug_cycles": 1,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.BP.5201",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 469,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 603,
    "drug_cycles": 2,
    "regimen_number": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 476,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "BORTEZOMIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1476,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1742,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1962,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 2053,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 512,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 816,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1868,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1883,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "NAB-RAPAMYCIN",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1213,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1468,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "INTERFERON ALFA 2A",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 476,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "INTERFERON ALFA 2B",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 484,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 507,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 849,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 861,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4637",
    "drug_therapy_name": "CEDIRANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1868,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1888,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4638",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 160,
    "drug_cycles": 5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4638",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 252,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 281,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4638",
    "drug_therapy_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 252,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4638",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 192,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 221,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4641",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 321,
    "drug_cycles": 9,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4644",
    "drug_therapy_name": "ERLOTINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 316,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4644",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 316,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4644",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 229,
    "pharma_type_other": "VACCINE",
    "regimen_number": 1,
    "drug_route": "INTRAMUSCULAR",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4644",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 150,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 222,
    "drug_units": "G/DAY",
    "drug_dose": 2.5,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4644",
    "drug_therapy_name": "INTERFERON ALFA 2B",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 162,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 222,
    "drug_cycles": 1,
    "regimen_number": 2,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4868",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 89,
    "drug_cycles": 2,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4868",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 296,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 365,
    "drug_cycles": 3,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4868",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 379,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 534,
    "drug_cycles": 1,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4868",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 135,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 282,
    "drug_cycles": 10,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4868",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 296,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 365,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4868",
    "drug_therapy_name": "ERLOTINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 114,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 288,
    "drug_cycles": 10,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4869",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 767,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 854,
    "pharma_type_other": "SORAFENIB",
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.CJ.4869",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 881,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1963,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.CJ.4871",
    "drug_therapy_name": "INTERFERON ALFA",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 98,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 65,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4875",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1083,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 36,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4881",
    "drug_therapy_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1931,
    "pharmaceutical_tx_ongoing": true,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.CJ.4887",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 124,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER"
  },
  {
    "patient_ID": "TCGA.CJ.4888",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 576,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1456,
    "drug_cycles": 36,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4890",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 211,
    "drug_cycles": 4,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4890",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 263,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 444,
    "drug_cycles": 6,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4890",
    "drug_therapy_name": "TIPIFARNIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 263,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 444,
    "drug_cycles": 6,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4890",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1483,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1636,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4890",
    "drug_therapy_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1636,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1698,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4890",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 480,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1483,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4894",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 188,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 240,
    "drug_cycles": 3,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.CJ.4895",
    "drug_therapy_name": "ERLOTINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 45,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 228,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4895",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 255,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 740,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4895",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 255,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 740,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4895",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 45,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 559,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4900",
    "drug_therapy_name": "ERLOTINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": -92,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 0,
    "drug_cycles": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEO-ADJUVANT"
  },
  {
    "patient_ID": "TCGA.CJ.4900",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": -92,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 0,
    "drug_cycles": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEO-ADJUVANT"
  },
  {
    "patient_ID": "TCGA.CJ.4904",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 295,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 463,
    "drug_cycles": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4913",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 861,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1020,
    "drug_cycles": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.CJ.4918",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 45,
    "drug_cycles": 1,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.4923",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 192,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 379,
    "drug_cycles": 6,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5676",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 209,
    "drug_cycles": 13,
    "pharma_type_other": "VACCINE",
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.CJ.5676",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2227,
    "pharmaceutical_tx_ongoing": true,
    "drug_units": "MG/KG/DAY",
    "drug_dose": 800,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.CJ.5677",
    "drug_therapy_name": "INTERFERON ALFA",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 70,
    "drug_cycles": 2,
    "drug_dose": 2,
    "regimen_number": 2,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5677",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 70,
    "drug_cycles": 2,
    "drug_units": "G/M2",
    "drug_total_dose_units": "G/DAY",
    "drug_dose": 1,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 2
  },
  {
    "patient_ID": "TCGA.CJ.5677",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 378,
    "drug_cycles": 5,
    "drug_units": "MG/M2",
    "drug_dose": 600,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5678",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 93,
    "drug_cycles": 6,
    "drug_units": "ML",
    "drug_dose": 0.2,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "patient_ID": "TCGA.CJ.5679",
    "drug_therapy_name": "INTERFERON ALFA",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 116,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 274,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5679",
    "drug_therapy_name": "THALIDOMIDE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 547,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 599,
    "drug_units": "MG/DAY",
    "drug_dose": 100,
    "regimen_number": 5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5679",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 344,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 547,
    "drug_cycles": 16,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "regimen_number": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5679",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 274,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 344,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_total_dose_units": "MG/WK",
    "drug_dose": 1000,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 1970
  },
  {
    "patient_ID": "TCGA.CJ.5679",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 274,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 344,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5680",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 220,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 247,
    "drug_cycles": 15,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5680",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 275,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 616,
    "drug_cycles": 24,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5680",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 186,
    "drug_cycles": 12,
    "drug_units": "ML",
    "drug_total_dose_units": "ML",
    "drug_dose": 0.2,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 2.4
  },
  {
    "patient_ID": "TCGA.CJ.5680",
    "drug_therapy_name": "ERLOTINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 466,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 629,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 150,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5681",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 165,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 235,
    "drug_cycles": 3,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5681",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 135,
    "drug_cycles": 2,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5681",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 235,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 318,
    "drug_cycles": 4,
    "drug_units": "MG/KG",
    "drug_dose": 650,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5681",
    "drug_therapy_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 305,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 365,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.5682",
    "drug_therapy_name": "INTERFERON ALFA",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 813,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.6028",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 392,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 903,
    "drug_cycles": 2,
    "drug_units": "MG/M2",
    "drug_dose": 600,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.6028",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 392,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 903,
    "drug_cycles": 2,
    "drug_units": "MG/M2/DAY",
    "drug_dose": 1500,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.6028",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1033,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1625,
    "drug_units": "MG/DAY",
    "drug_dose": 400,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.6028",
    "drug_therapy_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 130,
    "pharma_type_other": "VACCINE",
    "drug_units": "ML",
    "drug_total_dose_units": "ML",
    "drug_dose": 0.4,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "TREATMENT OF METASTATIC DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY",
    "drug_total_dose": 3.6
  },
  {
    "patient_ID": "TCGA.CJ.6028",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 903,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1033,
    "drug_total_dose_units": "MG/DAY",
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 50
  },
  {
    "patient_ID": "TCGA.CJ.6028",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 336,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 392,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.6033",
    "drug_therapy_name": "CAPECITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 74,
    "drug_cycles": 2,
    "drug_units": "MG/DAY",
    "drug_dose": 2500,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "TREATMENT OF METASTATIC DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY"
  },
  {
    "patient_ID": "TCGA.CJ.6033",
    "drug_therapy_name": "INTERFERON",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 144,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 172,
    "drug_dose": 500000,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CJ.6033",
    "drug_therapy_name": "GEFITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 144,
    "drug_units": "MG/DAY",
    "drug_dose": 250,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METISTATIC DISEASE"
  },
  {
    "patient_ID": "TCGA.CJ.6033",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 144,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METISTATIC DISEASE"
  },
  {
    "patient_ID": "TCGA.CJ.6033",
    "drug_therapy_name": "GEMCITABINE",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 74,
    "drug_cycles": 2,
    "drug_units": "MG/M2/DAY",
    "drug_dose": 600,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "TREATMENT OF METASTATIC DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY"
  },
  {
    "patient_ID": "TCGA.CW.5580",
    "drug_therapy_name": "INTERFERON ALFA 2B",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 57
  },
  {
    "patient_ID": "TCGA.CW.5585",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2563
  },
  {
    "patient_ID": "TCGA.CW.5590",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 956,
    "pharma_type_other": "SU011248"
  },
  {
    "patient_ID": "TCGA.CW.5591",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 78
  },
  {
    "patient_ID": "TCGA.CW.6097",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 115,
    "pharmaceutical_tx_ongoing": false,
    "pharma_type_other": "CLINICAL TRIAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CZ.4857",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 228,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 247,
    "drug_cycles": 1,
    "pharma_type_other": "BIOLOGICAL THERAPY",
    "drug_units": "[IU]/KG",
    "drug_total_dose_units": "[IU]/KG",
    "drug_route": "INTRAVENOUS",
    "drug_total_dose": 1177
  },
  {
    "patient_ID": "TCGA.CZ.4858",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 1694,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1715,
    "drug_cycles": 2,
    "pharma_type_other": "BIOLOGICAL THERAPY",
    "drug_units": "[IU]/KG",
    "drug_total_dose_units": "[IU]/KG",
    "drug_dose": 600,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 1360
  },
  {
    "patient_ID": "TCGA.CZ.4860",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 132,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CZ.4861",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": -43,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 32,
    "drug_cycles": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "patient_ID": "TCGA.CZ.5454",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 324,
    "drug_cycles": 7,
    "drug_units": "MG/DAY",
    "drug_total_dose_units": "MG",
    "drug_dose": 37.5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 8925
  },
  {
    "patient_ID": "TCGA.CZ.5456",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1124,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1286,
    "drug_cycles": 4,
    "drug_units": "MG",
    "drug_dose": 800,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CZ.5460",
    "drug_therapy_name": "IL-2",
    "pharmaceutical_therapy_type.1": "OTHER",
    "days_to_drug_start": 174,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 298,
    "drug_cycles": 2,
    "pharma_type_other": "BIOLOGICAL THERAPY",
    "drug_units": "[IU]/KG",
    "drug_total_dose_units": "[IU]/KG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 2138
  },
  {
    "patient_ID": "TCGA.CZ.5461",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 45,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 278,
    "drug_cycles": 5,
    "drug_units": "MG/DAY",
    "drug_total_dose_units": "MG",
    "drug_dose": 50,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 7000
  },
  {
    "patient_ID": "TCGA.CZ.5462",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 15,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 127,
    "drug_units": "MG/DAY",
    "drug_dose": 50,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CZ.5464",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 571,
    "drug_units": "MG/DAY",
    "drug_dose": 50,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CZ.5464",
    "drug_therapy_name": "PAZOPANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1407,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1730,
    "drug_units": "MG",
    "drug_dose": 800,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.CZ.5469",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 223,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 597,
    "drug_units": "MG/DAY",
    "drug_dose": 37.5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "patient_ID": "TCGA.DV.5565",
    "drug_therapy_name": "VANDETANIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1189,
    "pharmaceutical_tx_ongoing": true,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_dose": 200,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "patient_ID": "TCGA.DV.A4VX",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 482,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "patient_ID": "TCGA.DV.A4VX",
    "drug_therapy_name": "SORAFENIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 482,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 1503,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "patient_ID": "TCGA.G6.A5PC",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 208,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.G6.A8L6",
    "drug_therapy_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type.1": "IMMUNOTHERAPY",
    "days_to_drug_start": 276,
    "pharmaceutical_tx_ongoing": true,
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.G6.A8L6",
    "drug_therapy_name": "SUNITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 73,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 211,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "patient_ID": "TCGA.G6.A8L6",
    "drug_therapy_name": "AXITINIB",
    "pharmaceutical_therapy_type.1": "CHEMOTHERAPY",
    "days_to_drug_start": 252,
    "pharmaceutical_tx_ongoing": false,
    "days_to_drug_end": 272,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  }
]
